-
公开(公告)号：US20110150923A1
公开(公告)日：2011-06-23
申请号：US13036007
申请日：2011-02-28
IPC分类号： A61K39/095 , A61K39/108 , A61P31/04 , A61K39/295
CPC分类号： A61K39/095 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/6037
摘要： The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.
摘要翻译： 本发明提供用于粘膜递送的免疫原性组合物，其包含来自脑膜炎奈瑟菌脑膜炎的血清群A，C，W135和Y的至少两个的荚膜糖。 本发明组合物中的荚膜糖优选与载体蛋白结合，和/或是寡糖。 共轭寡糖抗原是特别优选的。 本发明还提供免疫原性组合物，其包含（a）来自脑膜炎奈瑟氏球菌的血清群C的荚膜糖抗原和（b）壳聚糖佐剂。 组合物优选包含（c）一种或多种另外的抗原和/或（d）一种或多种另外的佐剂。 组合物特别适用于粘膜递送，包括鼻内递送。 使用壳聚糖和/或解毒的ADP-核糖基化毒素佐剂增强了抗脑膜炎球菌粘膜免疫应答，并且可以改变反应的Th1 / Th2偏差。
-
公开(公告)号：US20130243841A1
公开(公告)日：2013-09-19
申请号：US13700437
申请日：2011-06-01
申请人： Sushma Kommareddy , Derek O'Hagan , Manmohan Singh , Amanda Scampini Bonificio , Barbara Baudner
发明人： Sushma Kommareddy , Derek O'Hagan , Manmohan Singh , Amanda Scampini Bonificio , Barbara Baudner
IPC分类号： A61K9/00
CPC分类号： A61K9/0087 , A61K9/0019 , A61K9/19 , A61K39/12 , A61K39/145 , A61K47/26 , C12N7/00 , C12N2760/16134 , C12N2760/16151 , C12N2760/16234 , C12N2760/16251
摘要： A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens.
摘要翻译： 一种制备冻干疫苗抗原的方法，包括以下步骤：（i）使用离心过滤和/或超滤提高包含该抗原的液体组合物中的抗原浓度，以提供浓缩的抗原，和（ii）将浓缩的抗原冻干 ，以提供冻干的疫苗抗原。 冻干的材料可以重构并用于疫苗制剂。 该过程对流感疫苗抗原特别有用。
-
公开(公告)号：US20070207090A1
公开(公告)日：2007-09-06
申请号：US11599193
申请日：2006-11-13
申请人： Giuseppe Giudice , Barbara Baudner , Derek O'Hagan
发明人： Giuseppe Giudice , Barbara Baudner , Derek O'Hagan
IPC分类号： A61K39/095 , A61K39/02 , A61K9/12
CPC分类号： A61K39/095 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/6037
摘要： The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.
摘要翻译： 本发明提供用于粘膜递送的免疫原性组合物，其包含来自脑膜炎奈瑟菌脑膜炎的血清群A，C，W135和Y的至少两个的荚膜糖。 本发明组合物中的荚膜糖优选与载体蛋白结合，和/或是寡糖。 共轭寡糖抗原是特别优选的。 本发明还提供免疫原性组合物，其包含（a）来自脑膜炎奈瑟氏球菌的血清群C的荚膜糖抗原和（b）壳聚糖佐剂。 组合物优选包含（c）一种或多种另外的抗原和/或（d）一种或多种另外的佐剂。 组合物特别适用于粘膜递送，包括鼻内递送。 使用壳聚糖和/或解毒的ADP-核糖基化毒素佐剂增强了抗脑膜炎球菌粘膜免疫应答，并且可以改变反应的Th1 / Th2偏差。
-
4.发明授权公开(公告)号：US09827190B2
公开(公告)日：2017-11-28
申请号：US14764997
申请日：2014-01-30
申请人： Barbara Baudner , Simona Gallorini , Derek O'Hagan
发明人： Barbara Baudner , Simona Gallorini , Derek O'Hagan
IPC分类号： A61K9/00 , A61K39/39 , A61K39/095 , A61K39/145 , C12N7/00 , A61K39/00
CPC分类号： A61K9/0021 , A61K39/095 , A61K39/145 , A61K39/39 , A61K2039/545 , A61K2039/55511 , A61K2039/55544 , A61K2039/55572 , A61K2039/55583 , C12N7/00 , C12N2760/16134 , C12N2760/16171
摘要： An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.
-
公开(公告)号：US20130224245A1
公开(公告)日：2013-08-29
申请号：US13700436
申请日：2011-06-01
IPC分类号： A61K39/145
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2760/16134 , C12N2760/16151 , C12N2760/16234 , C12N2760/16251
摘要： An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating a vaccine from the concentrated antigen. The concentrated antigen is not lyophilised between or during steps (i) and (ii). The invention is particularly useful for preparing solid vaccine forms.
摘要翻译： 抗原浓缩程序不包括在其最终制剂和/或递送之前冻干本体抗原。 因此，制备疫苗的方法包括以下步骤：（i）增加包含该抗原的液体组合物中的抗原浓度，以提供浓缩抗原，和（ii）从浓缩抗原配制疫苗。 浓缩的抗原在步骤（i）和（ii）之间或之间不被冷冻干燥。 本发明特别可用于制备固体疫苗形式。
-
公开(公告)号：US20140112950A1
公开(公告)日：2014-04-24
申请号：US14002700
申请日：2012-03-02
申请人： Manmohan Singh , Barbara Baudner , David Skibinski
发明人： Manmohan Singh , Barbara Baudner , David Skibinski
IPC分类号： A61K39/00
CPC分类号： A61K39/0018 , A61K31/4375 , A61K31/66 , A61K33/06 , A61K39/102 , A61K39/116 , A61K39/12 , A61K39/295 , A61K39/39 , A61K2039/545 , A61K2039/55505 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C12N2730/10134 , C12N2770/32634 , Y02A50/466 , A61K2300/00
摘要： Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
摘要翻译： 组合疫苗组合物及其制备方法具有相对低量的抗原和/或相对低量的铝，但是它们仍可具有免疫原性，其可与具有相对高量抗原和/或 相对较高的铝量。 也提供了无铝组合疫苗组合物，例如， 用水包油乳剂佐剂佐剂化的组合物。
-
公开(公告)号：US20060051378A1
公开(公告)日：2006-03-09
申请号：US10514207
申请日：2003-05-14
申请人： Giuseppe Guidice , Barbara Baudner
发明人： Giuseppe Guidice , Barbara Baudner
IPC分类号： A61K39/108 , A61K31/722
CPC分类号： A61K39/095 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/6037
摘要： The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.
摘要翻译： 本发明提供免疫原性组合物，其包含（a）来自脑膜炎奈瑟氏球菌的血清群C的荚膜糖抗原和（b）壳聚糖佐剂。 组合物优选包含（c）一种或多种另外的抗原和/或（d）一种或多种另外的佐剂。 组合物特别适用于粘膜递送，包括鼻内递送。 本发明还提供用于粘膜递送的免疫原性组合物，其包含来自脑膜炎奈瑟菌脑膜炎的血清群A，C，W135和Y的至少两个的荚膜糖。 本发明组合物中的荚膜糖优选与载体蛋白结合，和/或是寡糖。 共轭寡糖抗原是特别优选的
-
公开(公告)号：US08926992B2
公开(公告)日：2015-01-06
申请号：US10514207
申请日：2003-05-14
IPC分类号： A61K39/095 , A61K39/108
CPC分类号： A61K39/095 , A61K2039/543 , A61K2039/55544 , A61K2039/55583 , A61K2039/6037
摘要： The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.
摘要翻译： 本发明提供免疫原性组合物，其包含（a）来自脑膜炎奈瑟氏球菌的血清群C的荚膜糖抗原和（b）壳聚糖佐剂。 组合物优选包含（c）一种或多种另外的抗原和/或（d）一种或多种另外的佐剂。 组合物特别适用于粘膜递送，包括鼻内递送。 本发明还提供用于粘膜递送的免疫原性组合物，其包含来自脑膜炎奈瑟菌脑膜炎的血清群A，C，W135和Y的至少两个的荚膜糖。 本发明组合物中的荚膜糖优选与载体蛋白结合，和/或是寡糖。 共轭寡糖抗原是特别优选的。
-
公开(公告)号：US20140363461A1
公开(公告)日：2014-12-11
申请号：US14240616
申请日：2012-08-31
申请人： Fabio Bagnoli , Barbara Baudner , Simone Bufali
发明人： Fabio Bagnoli , Barbara Baudner , Simone Bufali
IPC分类号： A61K39/085 , A61K39/39
CPC分类号： A61K39/085 , A61K39/39 , A61K2039/55505 , A61K2039/55511 , A61K2039/55572
摘要： The efficacy of S. aureus vaccines can be enhanced by adjuvanting S. aureus antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. A S. aureus antigen can also be adsorbed to the metal salt.
摘要翻译： 金黄色葡萄球菌疫苗的功效可以通过用TLR激动剂（优选TLR7激动剂）和不溶性金属盐（优选铝盐）的混合物佐剂金黄色葡萄球菌抗原来增强。 TLR激动剂通常被吸附到金属盐上。 金黄色葡萄球菌抗原也可以被吸附到金属盐上。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.022 秒)
